Spyre Therapeutics (SYRE) has completed enrollment in all sub-studies of its phase 2 SKYWAY basket trial of SPY072 in rheumatic diseases, the company said Wednesday.
The completed enrollment across the sub-studies keeps the company's planned slate of six phase 2 data readouts in 2026 on track, Spyre Therapeutics said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments